ArticleJournal of nucleic acids2012
Splicing programs and cancer.
Article in Journal of nucleic acids, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Platelet-Prostate cancer crosstalk driving disparities and therapeutic vulnerabilities.Discover oncology · 2026Review
- Modulation of alternative splicing during early infection of human primary B lymphocytes with Epstein-Barr virus (EBV): a novel function for the viral EBNA-LP protein.Nucleic acids research · 2021Article
- Alternative Splicing: Expanding the Landscape of Cancer Biomarkers and Therapeutics.International journal of molecular sciences · 2020Review
- Article
- Uncovering and characterizing splice variants associated with survival in lung cancer patients.PLoS computational biology · 2019Article
- Article
- Aberrant RNA Splicing in Cancer and Drug Resistance.Cancers · 2018Review
- Genetic variants of mucins: unexplored conundrum.Carcinogenesis · 2017Review
- MAP2 Splicing is Altered in Huntington's Disease.Brain pathology (Zurich, Switzerland) · 2017Article
- Faulty splicing and cytoskeleton abnormalities in Huntington's disease.Brain pathology (Zurich, Switzerland) · 2016Review
- Targeted alternative splicing of TAF4: a new strategy for cell reprogramming.Scientific reports · 2016Article
- MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.Cancer letters · 2016Article
- Alternative splicing within the Wnt signaling pathway: role in cancer development.Cellular oncology (Dordrecht, Netherlands) · 2016Review
- Global Profiling of the Cellular Alternative RNA Splicing Landscape during Virus-Host Interactions.PloS one · 2016Article
- Identification of recurrent regulated alternative splicing events across human solid tumors.Nucleic acids research · 2015Article
- HTLV-1-infected CD4+ T-cells display alternative exon usages that culminate in adult T-cell leukemia.Retrovirology · 2014Article
- Pre-mRNA splicing is facilitated by an optimal RNA polymerase II elongation rate.Genes & development · 2014Article
- The functional landscape of Hsp27 reveals new cellular processes such as DNA repair and alternative splicing and proposes novel anticancer targets.Molecular & cellular proteomics : MCP · 2014Article
- Nova1 is a master regulator of alternative splicing in pancreatic beta cells.Nucleic acids research · 2014Article
- The transcriptional co-activator SND1 is a novel regulator of alternative splicing in prostate cancer cells.Oncogene · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Numerous studies report splicing alterations in a multitude of cancers by using gene-by-gene analysis. However, understanding of the role of alternative splicing in cancer is now reaching a new level, thanks to the use of novel technologies allowing the analysis of splicing at a large-scale level. Genome-wide analyses of alternative splicing indicate that splicing alterations can affect the products of gene networks involved in key cellular programs. In addition, many splicing variants identified as being misregulated in cancer are expressed in normal tissues. These observations suggest that splicing programs contribute to specific cellular programs that are altered during cancer initiation and progression. Supporting this model, recent studies have identified splicing factors controlling cancer-associated splicing programs. The characterization of splicing programs and their regulation by splicing factors will allow a better understanding of the genetic mechanisms involved in cancer initiation and progression and the development of new therapeutic targets.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.